Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Biosearch Technologies, a supplier of oligonucleotide components to the rapidly growing molecular diagnostics industry, announced that it has acquired worldwide rights to TurboFISH technology, a method for rapid single molecule RNA FISH. With the TurboFISH license, Biosearch maintains exclusive access to continuing Stellaris RNA FISH-based inventions from Rutgers, The State University of New Jersey.
TriLink BioTechnologies, a provider of custom nucleic acid-based products, announced the launch of MitoPrimers, dilute-and-go primers for mitochondrial DNA PCR amplification and sequencing in forensic identification. The high sensitivity of mtDNA PCR amplification and sequencing allows forensic scientists to obtain information from evidence associated with homicides or other criminal investigations, body identifications, and cold cases, as well as small pieces of evidence containing little biological material.
Leica Biosystems has signed an agreement to supply HealthTrust, a group purchasing organization and provider of total cost management solutions for health care facilities, with its broad range of histology instrumentation, laboratory consumables, and sample-tracking systems.
Bio SB, a molecular pathology company based in Santa Barbara, Calif., has announced that it will partner with Cancer Diagnostics Inc. to distribute the Bio SB line of IHC antibodies, chromogens, and ancillaries in the U.S. market.
Diagnovus, a molecular diagnostics company focused on underserved, aggressive, and lesser-known diseases, announced the launch of the Engauge GI Barrett’s Esophagus genomic assay to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in Barrett’s esophagus patients.
Denville Scientific’s new Ultra EZpette high-precision digital pipettors provide accurate and precise liquid dispensing in an ergonomic design.
Horizon Discovery has signed a research service agreement with Blueprint Medicines, a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Under the terms of the deal, Horizon will support Blueprint’s New Targets discovery platform by deploying its X-Man isogenic cell lines.
Beckman Coulter Life Sciences has received 510(k) clearance from the FDA and an import medical device registration certificate from the China Food and Drug Administration for the in vitro diagnostic use of the Navios flow cytometry system.
Ventana Medical Systems announced the global launch of its BRAF V600E immunohistochemistry test to detect the BRAF V600E mutation in a variety of tumors. The test, launched as a U.S. class I exempt/CE-IVD product, is designed to detect the most frequent BRAF mutation, V600E, which has been found to play a key role in a variety of cancers, including colorectal cancer.
Audit MicroControls has added Control LQ Spinal Fluid to its line of daily quality control products. This bi-level reference control consisting of human serum-based solutions simulates patient spinal fluid samples for monitoring the precision of laboratory testing procedures for chloride, glucose, IgA, IgG, IgM, lactate, LDH, microalbumin, microprotein, and sodium.
